Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: Patients with seizures for six years or less

Sandra L. Helmers, David A. Griesemer, J. Christine Dean, Jorge D. Sanchez, Douglas Labar, Jerome V. Murphy, David Bettis, Yong D Park, Robert M. Shuman, George L. Morris

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100% was reported in 7.8% (early) and 3.7% (late) patients at 3 months and 11.8% (early) and 4.5% (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90% for early and late treatment groups were similar: 11.8% (early) and 11.0% (late) at 3 months and 23.5% (early) and 17.0% (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalNeurologist
Volume9
Issue number3
DOIs
StatePublished - May 1 2003

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Seizures
Therapeutics
Age of Onset
Registries

Keywords

  • Database
  • Epilepsy
  • Registry
  • Seizures
  • Vagus nerve stimulation therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy : Patients with seizures for six years or less. / Helmers, Sandra L.; Griesemer, David A.; Dean, J. Christine; Sanchez, Jorge D.; Labar, Douglas; Murphy, Jerome V.; Bettis, David; Park, Yong D; Shuman, Robert M.; Morris, George L.

In: Neurologist, Vol. 9, No. 3, 01.05.2003, p. 160-164.

Research output: Contribution to journalReview article

Helmers, SL, Griesemer, DA, Dean, JC, Sanchez, JD, Labar, D, Murphy, JV, Bettis, D, Park, YD, Shuman, RM & Morris, GL 2003, 'Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: Patients with seizures for six years or less', Neurologist, vol. 9, no. 3, pp. 160-164. https://doi.org/10.1097/00127893-200305000-00004
Helmers, Sandra L. ; Griesemer, David A. ; Dean, J. Christine ; Sanchez, Jorge D. ; Labar, Douglas ; Murphy, Jerome V. ; Bettis, David ; Park, Yong D ; Shuman, Robert M. ; Morris, George L. / Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy : Patients with seizures for six years or less. In: Neurologist. 2003 ; Vol. 9, No. 3. pp. 160-164.
@article{20af886e37ec426bafa554e33f94c540,
title = "Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy: Patients with seizures for six years or less",
abstract = "BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100{\%} was reported in 7.8{\%} (early) and 3.7{\%} (late) patients at 3 months and 11.8{\%} (early) and 4.5{\%} (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90{\%} for early and late treatment groups were similar: 11.8{\%} (early) and 11.0{\%} (late) at 3 months and 23.5{\%} (early) and 17.0{\%} (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.",
keywords = "Database, Epilepsy, Registry, Seizures, Vagus nerve stimulation therapy",
author = "Helmers, {Sandra L.} and Griesemer, {David A.} and Dean, {J. Christine} and Sanchez, {Jorge D.} and Douglas Labar and Murphy, {Jerome V.} and David Bettis and Park, {Yong D} and Shuman, {Robert M.} and Morris, {George L.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1097/00127893-200305000-00004",
language = "English (US)",
volume = "9",
pages = "160--164",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Observations on the use of vagus nerve stimulation earlier in the course of pharmacoresistant epilepsy

T2 - Patients with seizures for six years or less

AU - Helmers, Sandra L.

AU - Griesemer, David A.

AU - Dean, J. Christine

AU - Sanchez, Jorge D.

AU - Labar, Douglas

AU - Murphy, Jerome V.

AU - Bettis, David

AU - Park, Yong D

AU - Shuman, Robert M.

AU - Morris, George L.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100% was reported in 7.8% (early) and 3.7% (late) patients at 3 months and 11.8% (early) and 4.5% (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90% for early and late treatment groups were similar: 11.8% (early) and 11.0% (late) at 3 months and 23.5% (early) and 17.0% (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.

AB - BACKGROUND - This study retrospectively compared the effectiveness of vagus nerve stimulation (VNS) therapy among a constant cohort of patients in the patient outcome registry, which systematically monitors outcomes of patients receiving VNS therapy. Patients in the study had pharmacoresistant seizures for 6 years or less (early treatment group) or more than 6 years (late treatment group) before initiation of VNS therapy, and results are provided after both 3 and 12 months. REVIEW SUMMARY - Of 405 patients, 51 were in the early and 354 in the late treatment groups. Median age at onset of seizures was 7 years in the early and 4.5 years in the late treatment group. Seizure reduction of 100% was reported in 7.8% (early) and 3.7% (late) patients at 3 months and 11.8% (early) and 4.5% (late) at 12 months (P = 0.033). Reductions in seizure frequency greater than or equal to 90% for early and late treatment groups were similar: 11.8% (early) and 11.0% (late) at 3 months and 23.5% (early) and 17.0% (late) at 12 months. CONCLUSIONS - Patients treated earlier with VNS therapy were twice as likely to report no seizures as patients who had seizures for more than 6 years before they received VNS therapy. The effectiveness of VNS therapy should be assessed among other patients with pharmacoresistant seizures and lesser cumulative seizure loads.

KW - Database

KW - Epilepsy

KW - Registry

KW - Seizures

KW - Vagus nerve stimulation therapy

UR - http://www.scopus.com/inward/record.url?scp=0038689164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038689164&partnerID=8YFLogxK

U2 - 10.1097/00127893-200305000-00004

DO - 10.1097/00127893-200305000-00004

M3 - Review article

C2 - 12808412

AN - SCOPUS:0038689164

VL - 9

SP - 160

EP - 164

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 3

ER -